An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs MTX 110 (Primary) ; Gadoteridol
- Indications Glioma
- Focus Adverse reactions; First in man
- 11 Oct 2019 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.
- 11 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 25 May 2018 Status changed from planning to recruiting, according to a Midatech Pharma US media release.